Vorolanib
- Generic Name
- Vorolanib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C23H26FN5O3
- CAS Number
- 1013920-15-4
- Unique Ingredient Identifier
- YP8G3I74EL
- Background
Vorolanib is under investigation in clinical trial NCT03904719 (CM082 and JS001 in Patients With Advanced Small-cell Lung Cancer (SCLC)).
- Indication
与依维莫司联合，用于既往接受过酪氨酸激酶抑制剂治疗失败的晚期肾细胞癌患者。
- Associated Conditions
- -
- Associated Therapies
- -
Vorolanib Combined With Cadonilimab in the Treatment of Untreated Advanced RCC Patients
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-08-29
- Last Posted Date
- 2024-08-29
- Target Recruit Count
- 37
- Registration Number
- NCT06577961
Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2020-05-04
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 11
- Registration Number
- NCT04373369
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-07-11
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 88
- Registration Number
- NCT03583086
- Locations
- 🇺🇸
Baptist Clinical Research Institute, Memphis, Tennessee, United States
🇺🇸Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2018-04-27
- Last Posted Date
- 2020-07-29
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 16
- Registration Number
- NCT03511222
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath